Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma

被引：26

作者：

DeLeon, Thomas T. ^{[1
]}

Ahn, Daniel H. ^{[1
]}

Bogenberger, James M. ^{[1
]}

Anastasiadis, Panos Z. ^{[2
]}

Arora, Mansi ^{[1
]}

Ramanathan, Ramesh K. ^{[1
]}

Aqel, Bashar A. ^{[3
]}

Vasmatzis, George ^{[4
]}

Truty, Mark J. ^{[5
]}

Oklu, Rahmi ^{[6
]}

Bekaii-Saab, Tanios S. ^{[1
]}

Borad, Mitesh J. ^{[1
]}

机构：

[1] Mayo Clin, Dept Med, Div Hematol Oncol, Scottsdale, AZ 85259 USA

[2] Mayo Clin, Dept Canc Biol, Jacksonville, FL 32224 USA

[3] Mayo Clin, Dept Med, Div Gastroenterol & Hepatol, Scottsdale, AZ 85259 USA

[4] Mayo Clin, Dept Lab Med & Pathol, Dept Mol Med, Rochester, MN 55902 USA

[5] Mayo Clin, Dept Surg, Div Hepatobiliary & Pancreat Surg, Rochester, MN 55902 USA

[6] Mayo Clin, Dept Radiol, Div Intervent Radiol, Scottsdale, AZ 85259 USA

来源：

FUTURE ONCOLOGY | 2018年 / 14卷 / 06期

关键词：

biomarkers; cholangiocarcinoma; gallbladder cancer; hepatocellular cancer; immunotherapy; targeted therapy; GROWTH-FACTOR-RECEPTOR; TELOMERE TERMINAL TRANSFERASE; C-MET EXPRESSION; INTRAHEPATIC CHOLANGIOCARCINOMA; MUTATIONAL LANDSCAPE; PROGNOSTIC-SIGNIFICANCE; NEGATIVE REGULATOR; CLINICAL-RESPONSE; TUMOR-SUPPRESSOR; RISING INCIDENCE;

D O I：

10.2217/fon-2017-0451

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Worldwide hepatobiliary cancers are the second leading cause of cancer related death. Despite their relevance, hepatobiliary cancers have a paucity of approved systemic therapy options. However, there are a number of emerging therapeutic biomarkers and therapeutic concepts that show promise. In hepatocellular carcinoma, nivolumab appears particularly promising and recently received US FDA approval. In intrahepatic cholangiocarcinoma, therapies targeting FGFR2 and IDH1 and immune checkpoint inhibitors are the furthest along and generating the most excitement. There are additional biomarkers that merit further exploration in hepatobiliary cancers including FGF19, ERRFI1, TERT, BAP1, BRAF, CDKN2A, tumor mutational burden and ERBB2 (HER2/neu). Development of new and innovative therapies would help address the unmet need for effective systemic therapies in advanced and metastatic hepatobiliary cancers.

引用

页码：553 / 566

页数：14

共 117 条

[1]

Abou-Alfa GK, 2016, J CLIN ONCOL, V34, P4073

[2] c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma [J].

Aishima, SI ;

Taguchi, KI ;

Sugimachi, K ;

Shimada, M ;

Sugimachi, K ;

Tsuneyoshi, M .

HISTOPATHOLOGY, 2002, 40 (03) :269-278

[3] Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma [J].

Ally, Adrian ;

Balasundaram, Miruna ;

Carlsen, Rebecca ;

Chuah, Eric ;

Clarke, Amanda ;

Dhalla, Noreen ;

Holt, Robert A. ;

Jones, Steven J. M. ;

Lee, Darlene ;

Ma, Yussanne ;

Marra, Marco A. ;

Mayo, Michael ;

Moore, Richard A. ;

Mungall, Andrew J. ;

Schein, Jacqueline E. ;

Sipahimalani, Payal ;

Tam, Angela ;

Thiessen, Nina ;

Cheung, Dorothy ;

Wong, Tina ;

Brooks, Denise ;

Robertson, A. Gordon ;

Bowlby, Reanne ;

Mungall, Karen ;

Sadeghi, Sara ;

Xi, Liu ;

Covington, Kyle ;

Shinbrot, Eve ;

Wheeler, David A. ;

Gibbs, Richard A. ;

Donehower, Lawrence A. ;

Wang, Linghua ;

Bowen, Jay ;

Gastier-Foster, Julie M. ;

Gerken, Mark ;

Helsel, Carmen ;

Leraas, Kristen M. ;

Lichtenberg, Tara M. ;

Ramirez, Nilsa C. ;

Wise, Lisa ;

Zmuda, Erik ;

Gabriel, Stacey B. ;

Meyerson, Matthew ;

Cibulskis, Carrie ;

Murray, Bradley A. ;

Shih, Juliann ;

Beroukhim, Rameen ;

Cherniack, Andrew D. ;

Schumacher, Steven E. ;

Saksena, Gordon .

CELL, 2017, 169 (07) :1327-+

[4] Changing Hepatocellular Carcinoma Incidence and Liver Cancer Mortality Rates in the United States [J].

Altekruse, Sean F. ;

Henley, S. Jane ;

Cucinelli, James E. ;

McGlynn, Katherine A. .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 (04) :542-553

[5] Loss of BAP1 Expression Occurs Frequently in Intrahepatic Cholangiocarcinoma [J].

Andrici, Juliana ;

Goeppert, Benjamin ;

Sioson, Loretta ;

Clarkson, Adele ;

Renner, Marcus ;

Stenzinger, Albrecht ;

Tayao, Michael ;

Watson, Nicole ;

Farzin, Mahtab ;

Toon, Christopher W. ;

Smith, Ross C. ;

Mittal, Anubhav ;

Samra, Jaswinder S. ;

Hugh, Thomas J. ;

Chou, Angela ;

Lawlor, Rita T. ;

Weichert, Wilko ;

Schirmacher, Peter ;

Sperandio, Nicola ;

Ruzzenente, Andrea ;

Scarpa, Aldo ;

Gill, Anthony J. .

MEDICINE, 2016, 95 (02)

[6]

[Anonymous], 2013, J. Clin. Oncol, DOI DOI 10.1200/JCO.2013.31.15_SUPPL.2501

[7]

[Anonymous], N ENGL J MED

[8] Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: Interim results of KEYNOTE-028 [J].

Bang, Y. J. ;

Doi, T. ;

De Braud, F. ;

Piha-Paul, S. ;

Hollebecque, A. ;

Razak, A. R. Abdul ;

Lin, C. C. ;

Ott, P. A. ;

He, A. R. ;

Yuan, S. S. ;

Koshiji, M. ;

Lam, B. ;

Aggarwal, R. .

EUROPEAN JOURNAL OF CANCER, 2015, 51 :S112-S112

[9] A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma [J].

Bekaii-Saab, Tanios ;

Williams, Nita ;

Plass, Christoph ;

Calero, Miguel Villalona ;

Eng, Charis .

BMC CANCER, 2006, 6 (1)

[10] Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers [J].

Bekaii-Saab, Tanios ;

Phelps, Mitch A. ;

Li, Xiaobai ;

Saji, Motoyasu ;

Goff, Laura ;

Kauh, John Sae Wook ;

O'Neil, Bert H. ;

Balsom, Stephanie ;

Balint, Catherine ;

Liersemann, Ryan ;

Vasko, Vasily V. ;

Bloomston, Mark ;

Marsh, William ;

Doyle, L. Austin ;

Ellison, Gilian ;

Grever, Michael ;

Ringel, Matthew D. ;

Villalona-Calero, Miguel A. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (17) :2357-2363

← 1 2 3 4 5 6 7 8 9 10 →